Allergic Rhinitis-Current Pharmacotherapy

Otolaryngologic Clinics of North America

Volumn 41, Issue 2, 2008, Pages 347-358

  Krouse, John H ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ASTEMIZOLE; AZELASTINE; BECLOMETASONE DIPROPIONATE; CETIRIZINE; CHLORPHENIRAMINE MALEATE; CORTICOSTEROID; CYPROHEPTADINE; DECONGESTIVE AGENT; DESLORATADINE; DIPHENHYDRAMINE; FEXOFENADINE; HYDROXYZINE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LEVOCETIRIZINE; LORATADINE; MONTELUKAST; OLOPATADINE; PHENYLEPHRINE; PHENYLPROPANOLAMINE; PLACEBO; PROMETHAZINE; PSEUDOEPHEDRINE; TERFENADINE; TRIPELENNAMINE; UNINDEXED DRUG; VASOCONSTRICTOR AGENT; XYLOMETAZOLINE; ZAFIRLUKAST; ZILEUTON;

ALLERGIC CONJUNCTIVITIS; ALLERGIC RHINITIS; ASTHMA; BLURRED VISION; CARDIOTOXICITY; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEART BEAT; HEART DISEASE; HEART PALPITATION; HUMAN; HYPERTENSION; INSOMNIA; LIPOPHILICITY; LIVER TOXICITY; NERVOUSNESS; NOSE CONGESTION; NOSE POLYP; PSYCHOMOTOR DISORDER; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT ALLERGY; RESTLESSNESS; REVIEW; RHINITIS; SEDATION; SIDE EFFECT; SKIN ALLERGY; STROKE; TACHYCARDIA; TACHYPHYLAXIS; TREMOR; UNSPECIFIED SIDE EFFECT; URINE RETENTION; XEROSTOMIA;

ANTI-INFLAMMATORY AGENTS; CHOLINERGIC ANTAGONISTS; DRUG THERAPY; EXPECTORANTS; HISTAMINE H1 ANTAGONISTS; HUMANS; IMMUNOGLOBULIN E; LEUKOTRIENE ANTAGONISTS; NASAL DECONGESTANTS; RHINITIS, ALLERGIC, PERENNIAL;

EID: 40149109343     PISSN: 00306665     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.otc.2007.11.014     Document Type: Review

References (24)

1. Asthma and Allergy Foundation of America (AAFA). Consumer survey 2005. Available at: www.aafa.org/display.cfm?id=7&sub=92&cont=529. Accessed September 30, 2007.
2. Baroody F.M. Allergic rhinitis: broader disease effects and implications for management. Otolaryngol Head Neck Surg 128 (2003) 616-631
3. Sullivan P.W., Follin S.L., and Nichol M.B. Cost-benefit analysis of first-generation antihistamines in the treatment of allergic rhinitis. Pharmacoeconomics 22 (2004) 929-942
4. 1-receptor antagonists. Ann Allergy Asthma Immunol 66 (1991) 5-17
5. Pratt C., Brown A.M., Rumpe D., et al. Cardiovascular safety of fexofenadine HCl. Clin Exp Allergy 29 Suppl 3 (1999) 212-216
6. Philpot E.E. Safety of second-generation antihistamines. Asthma Allergy Prox 21 (2000) 15-20
7. Canonica G.W., Tarentini F., Compalati E., et al. Efficacy of desloratadine in the treatment of allergic rhinitis: a meta-analysis of randomized, double-blind, controlled trials. Allergy 62 (2007) 359-366
8. Bachert C., Bousquet J., Canonica G.W., et al. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol 114 (2004) 838-844
9. Berger W., Hampel Jr. F., Bernstein J., et al. Impact of azelastine nasal spray on symptoms and quality of life compared with cetirizine oral tablets in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 97 (2006) 375-381
10. Corren J., Storms W., Bernstein J., et al. Effectiveness of azelastine nasal spray compared with oral cetirizine in patients with seasonal allergic rhinitis. Clin Ther 27 (2005) 543-553
11. Kernan W.N., Viscoli C.M., Brass L.M., et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 343 (2000) 1826-1832
12. Creticos P.S., Peters S.P., Adkinson Jr. N.F., et al. Peptide leukotriene release after antigen challenge in patients sensitive to ragweed. N Engl J Med 310 (1984) 1626-1630
13. Nayak A., and Langdon R.B. Montelukast in the treatment of allergic rhinitis: an evidence-based review. Drugs 67 (2007) 887-901
14. Bousquet J., Van Cauwenberge P., Khaltiev N., et al. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 108 (2001) S147-S334
15. Mygind N., and Naclerio R.M. Intranasal corticosteroids. In: Naclerio R.M., Mygind N., Durham S.R., et al. (Eds). Rhinitis: mechanisms and management (1999), Marcel Dekker, New York
16. Mandl M., Nolop K., and Lutsky B.N. Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. Ann Allergy Asthma Immunol 79 (1997) 237-245
17. 1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol 89 (2002) 479-484
18. Nielsen L.P., and Dahl R. Comparison of intranasal corticosteroids and antihistamines in allergic rhinitis: a review of randomized, controlled trials. Am J Respir Med 2 (2003) 55-65
19. Skoner D.P., Rachelefsky G.S., Meltzer E.O., et al. Detection of growth suppression in children during treatment with beclomethasone dipropionate. Pediatrics 105 (2000) E23
20. Schenkel E.J., Skoner D.P., Bronsky E.A., et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics 105 (2000) E22
21. Allen D.B., Meltzer E.O., Lemanske Jr. R.F., et al. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc 23 (2002) 407-413
22. Yuta A., and Baraniuk J.N. Therapeutic approaches to mucus hypersecretion. Curr Allergy Asthma Rep 5 (2005) 243-251
23. Druce H.M. Adjuncts to medical management of sinusitis. Otolaryngol Head Neck Surg 103 (1990) 880-883
24. Berger W.E. Treatment of allergic rhinitis and other immunoglobulin E-mediated diseases with anti-immunoglobulin E antibody. Allergy Asthma Proc 27 (2006) S29-S32